Don’t Jump to Ubrelvy or Reyvow for Acute Migraine Treatment
March 2020
You’ll see new oral meds to treat acute migraine in adults, Ubrelvy (yoo-BREL-vee, ubrogepant) and Reyvow (RAY-vow, lasmiditan).
Ubrelvy is the first “gepant”...expect rimegepant to follow. They block receptors of calcitonin gene-related peptide (CGRP), a vasodilator and pain sensitizer that spikes during migraine attacks.
They’re different than the injectables for PREVENTION (Aimovig, Ajovy, Emgality)...monoclonal antibodies that block CGRP effects.
Get concise, unbiased advice for effective drug therapy, plus CE/CME
Prescriber Insights: PA includes:
- Cutting-edge advice about new medications and how they fit into practice
- Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
- Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations
Already a subscriber? Log in
Volume pricing available. Get a quote